You are here: Industry Insights > Inhibitor

News List

Has the Booming PD-1 Inhibitor Reached its Limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
Weekly Pharma News Review | PharmaSources.com (March 14 to 18) PharmaSources/Caicai
March 25, 2022
One of the most exciting news of this week was the marketing approval of duvelisib capsules, a dual PI3K inhibitor introduced by CSPC Pharmaceutical Group Co., Ltd.
NASDAQ Biopharma IPOs in the First Half of Q1 2022 David Orchard-Webb
March 01, 2022
So far in the first half of Q1 2022 seven biopharma companies have IPO’d on the NASDAQ.
Weekly Pharmaceutical News Review of PharmaSources.com (January 17th to 21st) PharmaSources/Caicai
January 25, 2022
The news review in this week is from January 17 to 21, covering a total of 19 pieces of information in 4 sections, i.e. review, transaction, R&D, and listing.
Weekly Pharma News Review of PharmaSources.com (January 10th to 14th) PharmaSources/Caicai
January 21, 2022
This week in review is the news from January 10-14, covering a total of 15 pieces of information in 3 sections, i.e. review, transaction, and R&D.
Fierce Competition of R&D of KRAS G12C Inhibitors PharmaSources/Yi
January 13, 2022
Recently, the class 1 new drug "ZG19018 Tablets" of Suzhou Zelgen Biopharmaceuticals Co., Ltd. is approved for clinical use in China and the indications are: advanced malignant solid tumors with KRAS G12C mutation.
Pharmaceutical News of the Week (July. 20th-July. 24th) | PharmaSources.com - Updates on R&D PharmaSources/Caicai
July 29, 2020
The hottest event of the week was the official kick-off of the centralized procurement of the third batch of pharmaceutical products organized in China, with 86 specifications started to be acquired the basic information.
Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA PR NEWSWIRE
November 22, 2024
Ascentage Pharma announced that a NDA for its inhouse developed investigational novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575)has been accepted and recommended the Priority Review designation CDE and NMPA.
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China PharmaSources
November 15, 2024
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China PharmaSources
September 19, 2024
InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Previous page 1 2 3 4 5 Next page